Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004;31(3):214-9.

Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation

Guilherme V Silva  1 , Emerson C Perin, Hans F R Dohmann, Radovan Borojevic, Suzana A Silva, Andre L S Sousa, Joao A R Assad, William K Vaughn, Claudio T Mesquita, Luciano Belém, Antonio C Carvalho, Hans J F Dohmann, Ellen Barroso do Amaral, Joaquim Coutinho, Rodrigo Branco, Edie Oliveira, James T Willerson
Affiliations
Clinical Trial

Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation

Guilherme V Silva et al. Tex Heart Inst J. 2004.

Abstract

Growing evidence suggests that transplantation of autologous bone-marrow mononuclear cells (ABMMNCs) can improve the perfusion and contractile function of ischemic myocardium. This procedure could potentially benefit transplant candidates awaiting a donor heart. To study the safety and feasibility of ABMMNC injection, we performed a prospective, nonrandomized, open-label study in 5 heart transplant candidates with severe ischemic heart failure. Each patient underwent baseline single-photon emission computed tomography, a ramp treadmill protocol, 2-dimensional echocardiography, 24-hour Holter monitoring, and signal-averaged electrocardiography, which were repeated at 2 and 6 months. Transendocardial delivery of ABMMNCs was done with the aid of electromechanical mapping to identify viable myocardium. Each patient received 15 ABMMNC injections of 0.2 cc each. There were no deaths, significant arrhythmias, or other major complications. The ABMMNC injection reduced the amount of ischemic myocardium (not statistically significant). More important, exercise test results improved significantly. Myocardial volume oxygen consumption increased from 10.6 +/- 3 mL/kg/min (baseline) to 16.3 +/- 7 mL/kg/min (2 months) and 23 +/- 7 mL/kg/min (6 months) (P = 0.0091). In 4 of the 5 cases, this was such an improvement that the patients were no longer eligible for cardiac transplantation. In addition, metabolic equivalents improved from 3.03 +/- 0.66 (baseline) to 4.65 +/- 1.99 (2 months) and 6.5 +/- 2.0 (6 months) (P = 0.0092). In conclusion, ABMMNC injections were performed safely and resulted in improved exercise capacity. This technique may hold promise as an alternative to medical management in patients with severe ischemic heart failure who are ineligible for conventional revascularization.

PubMed Disclaimer

Figures

None
Fig. 1 Myocardial volume oxygen consumption (mVOM/2) at baseline, 2 months, and 6 months.
None
Fig. 2 Metabolic equivalents (METS) at baseline, 2 months, and 6 months.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2000. [[{thij}<rf id='r1-6'>1. <urf>American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2000.</urf></rf> ]] BOO!
    1. Hunt SA, Frazier OH. Mechanical circulatory support and cardiac transplantation. Circulation 1998;97:2079–90. [[{thij}<rf id='r2-6'>2. <urf>Hunt SA, Frazier OH. Mechanical circulatory support and cardiac transplantation. Circulation 1998;97:2079–90.</urf></rf> ]] BOO! - PubMed
    1. International Society for Heart and Lung Transplantation. ISHLT Transplant Registry Quarterly Reports. Addison (TX): International Society for Heart and Lung Transplantation; 2001. [[{thij}<rf id='r3-6'>3. <urf>International Society for Heart and Lung Transplantation. ISHLT Transplant Registry Quarterly Reports. Addison (TX): International Society for Heart and Lung Transplantation; 2001.</urf></rf> ]] BOO!
    1. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001;345:1435–43. [[{thij}<rf id='r4-6'>4. <urf>Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001;345:1435–43.</urf></rf> ]] BOO! - PubMed
    1. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701–5. [[{thij}<rf id='r5-6'>5. <urf>Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701–5.</urf></rf> ]] BOO! - PubMed

Publication types